BR9911774A - Uso de interferon alfa 5 no tratamento das hepatopatias virais - Google Patents
Uso de interferon alfa 5 no tratamento das hepatopatias viraisInfo
- Publication number
- BR9911774A BR9911774A BR9911774-6A BR9911774A BR9911774A BR 9911774 A BR9911774 A BR 9911774A BR 9911774 A BR9911774 A BR 9911774A BR 9911774 A BR9911774 A BR 9911774A
- Authority
- BR
- Brazil
- Prior art keywords
- livers
- treatment
- liver diseases
- interferon alfa
- ifn
- Prior art date
Links
- 230000003612 virological effect Effects 0.000 title abstract 4
- 102000006992 Interferon-alpha Human genes 0.000 title abstract 3
- 108010047761 Interferon-alpha Proteins 0.000 title abstract 3
- 229950000038 interferon alfa Drugs 0.000 title abstract 3
- 208000019423 liver disease Diseases 0.000 title abstract 3
- 210000004185 liver Anatomy 0.000 abstract 5
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 208000005176 Hepatitis C Diseases 0.000 abstract 1
- 102000014150 Interferons Human genes 0.000 abstract 1
- 108010050904 Interferons Proteins 0.000 abstract 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 239000002299 complementary DNA Substances 0.000 abstract 1
- 229940079322 interferon Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Steroid Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
Patente de Invenção: <B>"USO DE INTERFERON ALFA 5 NO TRATAMENTO DAS HEPATOPATIAS VIRAIS"<D>. A invenção refere-se ao uso de interferon alfa 5 no tratamento de hepatopatias virais. A invenção descreve a síntese reduzida de IFN<244>5 nos fígados de pacientes com hepatite C em comparação com fígados sadios. O subtipo de IFN expresso nos referidos fígados sadios correspondia apenas ao subtipo alfa 5 em comparação com os diferentes subtipos expressos em fígados doentes. A seq³ência SEQ ID N°: 1 mostra a seq³ência parcial de cDNA correspondente a IFN<244>5. Estas diferenças significativas entre os padrões de expressão de alguns fígados e outros demonstram a importância do uso deste subtipo de interferon na fabricação de composições úteis no tratamento de hepatopatias virais. A invenção descreve detalhadamente esta utilização em diferentes formas e processos, incluindo aqueles que utilizam a produção de proteínas recombinantes a partir de seq³ências do tipo SEQ ID N°: 1.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES009801003A ES2138565B1 (es) | 1998-05-13 | 1998-05-13 | Uso del interferon alfa 5 en el tratamiento de las hepatopatias viral es. |
| PCT/ES1999/000134 WO1999058143A1 (es) | 1998-05-13 | 1999-05-13 | Uso del interferon alfa 5 en el tratamiento de las hepatopatias virales |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9911774A true BR9911774A (pt) | 2001-02-06 |
Family
ID=8303773
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9911774-6A BR9911774A (pt) | 1998-05-13 | 1999-05-13 | Uso de interferon alfa 5 no tratamento das hepatopatias virais |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US6995133B1 (pt) |
| EP (1) | EP1077068B9 (pt) |
| JP (1) | JP2002514606A (pt) |
| CN (1) | CN1173738C (pt) |
| AT (1) | ATE214941T1 (pt) |
| AU (1) | AU753463B2 (pt) |
| BR (1) | BR9911774A (pt) |
| CA (1) | CA2335645C (pt) |
| DE (2) | DE69901099T4 (pt) |
| DK (1) | DK1077068T5 (pt) |
| ES (2) | ES2138565B1 (pt) |
| PT (1) | PT1077068E (pt) |
| RU (1) | RU2209079C2 (pt) |
| SE (1) | SE1077068T5 (pt) |
| WO (1) | WO1999058143A1 (pt) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110179530A1 (en) * | 2001-01-23 | 2011-07-21 | University Of Central Florida Research Foundation, Inc. | Pharmaceutical Proteins, Human Therapeutics, Human Serum Albumin Insulin, Native Cholera Toxin B Subunit on Transgenic Plastids |
| FR2824333B1 (fr) * | 2001-05-03 | 2003-08-08 | Genodyssee | Nouveaux polynucleotides et polypeptides de l'ifn alpha 5 |
| ES2303492A1 (es) * | 2004-08-18 | 2008-08-01 | Instituto Cientifico Y Tecnologico De Navarra S.A. | Uso del factor de crecimiento semejante a la insulina tipo i y de interferon alfa en el tratamiento de una enfermedad hepatica cronica, kit y composiciones que los comprenden. |
| WO2006032711A1 (es) * | 2004-08-18 | 2006-03-30 | Instituto Científico Y Tecnológico De Navarra S.A. | Uso del factor de crecimiento semejante a la insulina tipo i y de interferón alfa en el tratamiento de una enfermedad hepática crónica, kit y composiciones que los comprenden |
| MX2012008893A (es) * | 2010-02-01 | 2013-02-27 | Digna Biotech Sl | Procedimiento para la produccion de interferon alfa 5. |
| BR112013032188A2 (pt) | 2011-06-23 | 2016-12-20 | Digna Biotech Sl | composição, produto e método para tratar pacientes com hepatite c crônica |
| LT6164B (lt) | 2013-10-15 | 2015-06-25 | Uab Biotechnologinės Farmacijos Centras "Biotechpharma" | Sulieti interferono-alfa 5 baltymai su kitu citokinu ir jų gamybos būdas |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4973479A (en) * | 1982-01-15 | 1990-11-27 | Cetus Corporation | Interferon-α61 |
| PT503648E (pt) * | 1991-03-12 | 2000-10-31 | Biogen Inc | Dominio do antigenio 3 associado a funcao linfocitica de ligacao as cd2 |
| DE69528751T2 (de) * | 1994-03-07 | 2003-07-10 | Imperial College Of Science, Technology & Medicine | Verwendung von Interferon-alpha 8 subtype zur Herstellung von Medikamenten zur Behandlung von Viralinfektionen der Leber |
| US6172046B1 (en) * | 1997-09-21 | 2001-01-09 | Schering Corporation | Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection |
-
1998
- 1998-05-13 ES ES009801003A patent/ES2138565B1/es not_active Expired - Lifetime
-
1999
- 1999-05-13 AU AU37111/99A patent/AU753463B2/en not_active Ceased
- 1999-05-13 DE DE69901099T patent/DE69901099T4/de not_active Expired - Lifetime
- 1999-05-13 ES ES99919282T patent/ES2174604T3/es not_active Expired - Lifetime
- 1999-05-13 CA CA2335645A patent/CA2335645C/en not_active Expired - Fee Related
- 1999-05-13 JP JP2000547994A patent/JP2002514606A/ja active Pending
- 1999-05-13 AT AT99919282T patent/ATE214941T1/de active
- 1999-05-13 CN CNB998078662A patent/CN1173738C/zh not_active Expired - Fee Related
- 1999-05-13 WO PCT/ES1999/000134 patent/WO1999058143A1/es active IP Right Grant
- 1999-05-13 EP EP99919282A patent/EP1077068B9/en not_active Expired - Lifetime
- 1999-05-13 RU RU2000131172/14A patent/RU2209079C2/ru not_active IP Right Cessation
- 1999-05-13 SE SE99919282T patent/SE1077068T5/xx unknown
- 1999-05-13 US US09/674,445 patent/US6995133B1/en not_active Expired - Fee Related
- 1999-05-13 DK DK99919282T patent/DK1077068T5/da active
- 1999-05-13 PT PT99919282T patent/PT1077068E/pt unknown
- 1999-05-13 BR BR9911774-6A patent/BR9911774A/pt not_active Application Discontinuation
- 1999-05-13 DE DE69901099A patent/DE69901099D1/de not_active Expired - Lifetime
-
2005
- 2005-08-25 US US11/212,126 patent/US7501392B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2335645C (en) | 2011-01-04 |
| ATE214941T1 (de) | 2002-04-15 |
| SE1077068T5 (sv) | 2003-03-04 |
| ES2138565B1 (es) | 2000-08-16 |
| EP1077068A1 (en) | 2001-02-21 |
| CN1173738C (zh) | 2004-11-03 |
| JP2002514606A (ja) | 2002-05-21 |
| WO1999058143A9 (es) | 2002-08-22 |
| WO1999058143A1 (es) | 1999-11-18 |
| DE69901099D1 (de) | 2002-05-02 |
| CA2335645A1 (en) | 1999-11-18 |
| US7501392B2 (en) | 2009-03-10 |
| SE1077068T3 (sv) | 2002-07-02 |
| DE69901099T2 (de) | 2002-11-07 |
| RU2209079C2 (ru) | 2003-07-27 |
| ES2174604T3 (es) | 2002-11-01 |
| US20060188477A1 (en) | 2006-08-24 |
| EP1077068B9 (en) | 2002-10-02 |
| ES2138565A1 (es) | 2000-01-01 |
| AU753463B2 (en) | 2002-10-17 |
| US6995133B1 (en) | 2006-02-07 |
| CN1307482A (zh) | 2001-08-08 |
| EP1077068B1 (en) | 2002-03-27 |
| DK1077068T5 (da) | 2002-10-14 |
| PT1077068E (pt) | 2002-07-31 |
| DK1077068T3 (da) | 2002-07-22 |
| AU3711199A (en) | 1999-11-29 |
| DE69901099T4 (de) | 2003-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0009964A (pt) | Peptìdios artificiais com atividade desuperfìcie e sua utilização na preparação de surfactante artificial | |
| HUP0301444A2 (hu) | Ribavirin és pegilezett alfa-interferon alkalmazása HCV fertőzés kezelésére szolgáló gyógyszerkészítmény előállítására | |
| DE69922958D1 (de) | Hcv hüllproteine partikel : verwendung für therapeutische impfung | |
| HUP0003384A2 (hu) | Legalább egy, kettős szálú RNS és legalább egy, vírus elleni szer kombinációját tartalmazó termék | |
| AR021876A1 (es) | Terapia de combinacion para vhc por induccion de ribavirina - interferon alfa pegilado | |
| ES2186660T3 (es) | Terapia de combinacion para erradicar hcv-rna detectable en pacientes con infeccion por hepatitis c cronica. | |
| HUP0302334A2 (hu) | Vírusellenes hatású nukleozid-vegyületek prekurzorjai, valamint e vegyületek alkalmazása gyógyászati készítmények előállítására | |
| ATE402957T1 (de) | Analoge des menschlichen interferon-alpha mit niedriger toxizität | |
| ES2131811T3 (es) | Metodos y composiciones de proteinas modificadas n-terminalmente de forma quimica. | |
| DK1368060T3 (da) | HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme | |
| HK1002901A1 (en) | A composition used as a therapeutic agent against chronic viral hepatic diseases | |
| WO2004085633A8 (en) | A novel human virus causing severe acute respiratory syndrome (sars) and uses thereof | |
| BR9911774A (pt) | Uso de interferon alfa 5 no tratamento das hepatopatias virais | |
| BRPI0407533A (pt) | proteìnas de fusão e muteìnas do interferon alfa com propriedades melhoradas | |
| ATE256736T1 (de) | Ein nicht-mitogener kompetitiver hgf-antagonist | |
| ATE536878T1 (de) | Herstellung einer therapeutischen zusammensetzung | |
| ATE482272T1 (de) | Zytokinproteinfamilie | |
| PE20001386A1 (es) | Terapia de combinacion para el vhc por induccion de ribavirina-interferon alfa | |
| BR0108997A (pt) | Terapia imune adjuvante para hiv | |
| BR0311696A (pt) | Tratamento de hepatite c na população asiática com interferon-beta subcutâneo | |
| NO20053189L (no) | HVC-kombinasjonsterapi. | |
| ITRM20010336A1 (it) | Anticorpo umano ricombinante diretto contro la proteina non strutturale ns3 del virus dell'epatite c (hcv), acido nucleico codificante e usi | |
| BR0014803A (pt) | Peptìdeo, composição farmacêutica, uso de um ou mais dos peptìdeos, e, composição de diagnóstico | |
| ES2160927T3 (es) | Composiciones farmaceuticas que comprenden interferon alfa humano natural. | |
| IT1312060B1 (it) | Uso dell'acido alfa lipoico nel trattamento antimetastatico. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25A | Requested transfer of rights approved |
Free format text: FUNDACION PARA LA INVESTIGACION MEDICA APPLICADA (ES) |
|
| B25A | Requested transfer of rights approved |
Owner name: PROYECTO DE BIOMEDICINA CIMA, S.L. (ES) Free format text: TRANSFERIDO DE: FUNDACION PARA LA INVESTIGACION MEDICA APPLICADA |
|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 24 DA LPI. |
|
| B12B | Appeal against refusal [chapter 12.2 patent gazette] |